Clinical Trial Update: A Pilot Study on the Effects of ILARIS® on Patients With Proliferative Diabetic Retinopathy (PDRP) [Phase 1]

View source ↗

Summary

A Phase 1 pilot study evaluating ILARIS (canakinumab) for proliferative diabetic retinopathy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Diabetic Retinopathy

Drugs mentioned

• ILARIS (canakinumab)

Snippet

Sponsor: PD Dr. med. Stephan Michels | Conditions: Proliferative Diabetic Retinopathy | Phase 1 | Status: TERMINATED